Atlanta Braves Holdings (BATRK) CFO executes option exercise and sale under 10b5-1
Rhea-AI Filing Summary
Jill L. Robinson, EVP, CFO & Treasurer of Atlanta Braves Holdings, Inc. (BATRK), reported transactions dated 08/15/2025. She exercised a stock option to acquire 40,000 Series C shares at an exercise price of $27.18, which increased her reported beneficial ownership to 108,755 shares. On the same date she sold 40,000 Series C shares under a Rule 10b5-1 sales plan adopted May 15, 2025, at a weighted average sale price of $43.82 (range $43.68 to $44.12), leaving 68,755 Series C shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Positive
- Transactions were executed under a Rule 10b5-1 plan, adopted May 15, 2025, indicating prearranged compliance with insider trading rules.
- Option exercise and sale details are fully disclosed, including exercise price ($27.18), weighted average sale price ($43.82) and sale price range ($43.68–$44.12).
Negative
- Net direct beneficial ownership declined to 68,755 Series C shares after the reported sale on 08/15/2025.
- Large insider sale of 40,000 shares might be viewed as a reduction in the reporting person’s position (document contains no statement of purpose beyond the 10b5-1 plan).
Insights
TL;DR: Officer exercised options then sold an equal number of shares under a pre-established 10b5-1 plan; net direct holdings declined.
The filing shows a simultaneous option exercise and a planned sale of 40,000 Series C shares on 08/15/2025. Exercising at $27.18 and selling at a weighted average of $43.82 realized a spread but left the reporting person with fewer directly owned shares (68,755 after the sale). The sale was executed pursuant to a 10b5-1 plan adopted May 15, 2025, which indicates the transactions were prearranged and intended to provide the affirmative defense under Rule 10b5-1. The reporting structure and dates are clearly disclosed; no additional financial results or forward-looking statements are present.
TL;DR: Governance process followed: disclosure complete and sale executed under a formal 10b5-1 plan.
The Form 4 discloses material insider activity by a senior officer and identifies the use of a Rule 10b5-1 plan adopted May 15, 2025. The filing includes required details: transaction dates, prices, exercised option terms (exercise price $27.18; option exercisable 12/10/2023, expiring 12/10/2027), and the weighted average sale price with price range. The filing appears procedurally compliant and signed by an attorney-in-fact on 08/19/2025. There is no indication in the document of any undisclosed related-party arrangements or deviations from required reporting elements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (Right to Buy) - BATRK | 40,000 | $0.00 | $0.00 |
| Exercise | Series C Common Stock | 40,000 | $27.18 | $1.09M |
| Sale | Series C Common Stock | 40,000 | $43.82 | $1.75M |
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2025.
- F2. Reflects the weighted average sale price. The range of prices for such transaction is $43.68 to $44.12. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
AI-generated analysis. How Rhea-AI works. Not financial advice.
